Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
Sureda, Anna (Institut Català d'Oncologia)
Chabannon, Christian (Institut Paoli-Calmettes)
Masszi, Tamás (Semmelweis University)
Pohlreich, David (Charles University Hospital)
Scheid, Christof (University of Cologne)
Thieblemont, Catherine (Hôpital Saint-Louis)
Wahlin, Björn E. (Karolinska University Hospital and Karolinska Institutet (Suecia))
Sakellari, Ioanna (George Papanicolaou General Hospital (Tessalònica, Grècia))
Russell, Nigel (Nottingham University Hospital)
Janikova, Andrea (University Hospital Brno (República Txeca))
Dabrowska-Iwanicka, Anna (Maria Sklodowska-Curie Institute-Oncology Center)
Touzeau, Cyrille (CHU Nantes)
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau)
Jantunen, Esa (University of Eastern Finland and Kuopio University Hospital)
van der Werf, Steffie (EBMT Data Office)
Bosman, Paul (EBMT Data Office)
Boumendil, Ariane (EBMT Statistical Unit)
Liu, Qianying (Sanofi Genzyme)
Celanovic, Marina (Sanofi Genzyme)
Montoto, Silvia (St Bartholomew's Hospital)
Dreger, Peter (University of Heidelberg)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8. 3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1. 3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Immunopathogenesis ; Stem-cell therapies
Publicat a:	Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 613-622, ISSN 1476-5365

DOI: 10.1038/s41409-019-0693-z
PMID: 31570781

10 p, 856.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats